NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 174 filers reported holding NEVRO CORP in Q4 2016. The put-call ratio across all filers is 0.56 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $367,000 | -59.2% | 2,630 | -49.4% | 0.00% | -63.6% |
| Q4 2020 | $900,000 | +24.1% | 5,200 | 0.0% | 0.01% | +10.0% |
| Q3 2020 | $725,000 | -77.6% | 5,200 | -80.8% | 0.01% | -77.8% |
| Q2 2020 | $3,238,000 | +16.1% | 27,100 | -2.9% | 0.04% | +2.3% |
| Q1 2020 | $2,790,000 | -11.8% | 27,900 | +4.1% | 0.04% | +37.5% |
| Q4 2019 | $3,163,000 | +35.8% | 26,800 | -1.1% | 0.03% | +28.0% |
| Q3 2019 | $2,330,000 | +32.6% | 27,100 | 0.0% | 0.02% | +31.6% |
| Q2 2019 | $1,757,000 | +3986.0% | 27,100 | +5320.0% | 0.02% | – |
| Q1 2018 | $43,000 | +22.9% | 500 | 0.0% | 0.00% | – |
| Q4 2017 | $35,000 | -22.2% | 500 | 0.0% | 0.00% | – |
| Q3 2017 | $45,000 | +21.6% | 500 | 0.0% | 0.00% | – |
| Q2 2017 | $37,000 | -21.3% | 500 | 0.0% | 0.00% | – |
| Q1 2017 | $47,000 | +4600.0% | 500 | +12400.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 4 | 0.0% | 0.00% | – |
| Q2 2016 | $1,000 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |